Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
3 results
Results by year
Filters applied: . Clear all
Page 1
In Situ Nanofiber Formation Blocks AXL and GAS6 Binding to Suppress Ovarian Cancer Development.
Adv Mater. 2024 Mar 28:e2308504. doi: 10.1002/adma.202308504. Online ahead of print.
Adv Mater. 2024.
PMID: 38546279
Efficacy and Safety of Niraparib as First-Line Maintenance Treatment for Patients with Advanced Ovarian Cancer: Real-World Data from a Multicenter Study in China.
Zhao M, Qiu S, Wu X, Miao P, Jiang Z, Zhu T, Xu X, Zhu Y, Zhang B, Yuan D, Zhang Y, Sun W, He A, Zhao M, Hou W, Zhang Y, Shao Z, Jia M, Li M, Chen J, Xu J, Chen B, Zhou Y, Shen Y.
Zhao M, et al.
Target Oncol. 2023 Nov;18(6):869-883. doi: 10.1007/s11523-023-00999-x. Epub 2023 Oct 17.
Target Oncol. 2023.
PMID: 37847485
Free PMC article.
Item in Clipboard
Salt-Inducible Kinase 2-Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis.
Hua Y, Yin H, Liu X, Xie J, Zhan W, Liang G, Shen Y.
Hua Y, et al.
Adv Sci (Weinh). 2022 Aug;9(22):e2202260. doi: 10.1002/advs.202202260. Epub 2022 May 26.
Adv Sci (Weinh). 2022.
PMID: 35618488
Free PMC article.
Item in Clipboard
Cite
Cite